BACKGROUND: Current guidelines of Food and Drug Administration for the evaluation of SPECT myocardial perfusion imaging (MPI) in clinical trials recommend independent visual interpretation by multiple experts. Few studies have addressed whether quantitative SPECT MPI assessment would be more reproducible for this application. METHODS AND RESULTS: We studied 31 patients (age 68 +/- 13, 25 male) with abnormal stress MPI who underwent repeat exercise (n = 11) or adenosine (n = 20) MPI within 9-22 months (mean 14.9 +/- 3.8 months) and had no interval revascularization or myocardial infarction and no change in symptoms, stress type, rest or stress ECG, or clinical response to stress on the second study. Visual interpretation per FDA Guidance used 17-segment, 5-point scoring by two independent expert readers with overread of discordance by a third expert, and percent myocardium abnormal was derived from normalized summed scores. The quantitative magnitude of perfusion abnormality was assessed by the total perfusion deficit (TPD), expressing stress, rest, and ischemic perfusion abnormality. High linear correlations were observed between visual and quantitative size of stress, rest, and ischemic defects (R = 0.94, 0.92, 0.84). Correlations of two tests were higher by quantitative than by visual methods for stress (R = 0.97 vs R = 0.91, P = 0.03) and rest defects (R = 0.94 vs R = 0.82, P = 0.03), respectively, and statistically similar for ischemic defects (R = 0.84 vs R = 0.70, P = ns). CONCLUSIONS: In stable patients having serial SPECT MPI, quantification is more reproducible than visual for magnitude of perfusion abnormality, suggesting its superiority for use in randomized clinical trials and monitoring the effects of therapy in an individual patient.
BACKGROUND: Current guidelines of Food and Drug Administration for the evaluation of SPECT myocardial perfusion imaging (MPI) in clinical trials recommend independent visual interpretation by multiple experts. Few studies have addressed whether quantitative SPECT MPI assessment would be more reproducible for this application. METHODS AND RESULTS: We studied 31 patients (age 68 +/- 13, 25 male) with abnormal stress MPI who underwent repeat exercise (n = 11) or adenosine (n = 20) MPI within 9-22 months (mean 14.9 +/- 3.8 months) and had no interval revascularization or myocardial infarction and no change in symptoms, stress type, rest or stress ECG, or clinical response to stress on the second study. Visual interpretation per FDA Guidance used 17-segment, 5-point scoring by two independent expert readers with overread of discordance by a third expert, and percent myocardium abnormal was derived from normalized summed scores. The quantitative magnitude of perfusion abnormality was assessed by the total perfusion deficit (TPD), expressing stress, rest, and ischemic perfusion abnormality. High linear correlations were observed between visual and quantitative size of stress, rest, and ischemic defects (R = 0.94, 0.92, 0.84). Correlations of two tests were higher by quantitative than by visual methods for stress (R = 0.97 vs R = 0.91, P = 0.03) and rest defects (R = 0.94 vs R = 0.82, P = 0.03), respectively, and statistically similar for ischemic defects (R = 0.84 vs R = 0.70, P = ns). CONCLUSIONS: In stable patients having serial SPECT MPI, quantification is more reproducible than visual for magnitude of perfusion abnormality, suggesting its superiority for use in randomized clinical trials and monitoring the effects of therapy in an individual patient.
Authors: Peter G Danias; Alan W Ahlberg; Mark I Travin; Nicholas C Mahr; Joseph E Abreu; Dominic Marini; April Mann; Jeffrey F Mather; William E Boden; Gary V Heller Journal: J Nucl Cardiol Date: 2002 May-Jun Impact factor: 5.952
Authors: G Germano; P B Kavanagh; H T Su; M Mazzanti; H Kiat; R Hachamovitch; K F Van Train; J S Areeda; D S Berman Journal: J Nucl Med Date: 1995-06 Impact factor: 10.057
Authors: Ronald G Schwartz; Thomas A Pearson; Vijay G Kalaria; Maria L Mackin; Daniel J Williford; Ashish Awasthi; Abrar Shah; Adam Rains; Joseph J Guido Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Piotr J Slomka; Hidetaka Nishina; Daniel S Berman; Xingping Kang; John D Friedman; Sean W Hayes; Usaf E Aladl; Guido Germano Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057
Authors: Yuan Xu; Ryo Nakazato; Sean Hayes; Rory Hachamovitch; Victor Y Cheng; Heidi Gransar; Romalisa Miranda-Peats; Mark Hyun; Leslee J Shaw; John Friedman; Guido Germano; Daniel S Berman; Piotr J Slomka Journal: J Nucl Cardiol Date: 2011-09-20 Impact factor: 5.952
Authors: Balaji Tamarappoo; Damini Dey; Haim Shmilovich; Ryo Nakazato; Heidi Gransar; Victor Y Cheng; John D Friedman; Sean W Hayes; Louise E J Thomson; Piotr J Slomka; Alan Rozanski; Daniel S Berman Journal: JACC Cardiovasc Imaging Date: 2010-11
Authors: Albert Flotats; Paco E Bravo; Kenji Fukushima; Muhammad A Chaudhry; Jennifer Merrill; Frank M Bengel Journal: Eur J Nucl Med Mol Imaging Date: 2012-05-31 Impact factor: 9.236
Authors: Ryo Nakazato; Daniel S Berman; Sean W Hayes; Mathews Fish; Richard Padgett; Yuan Xu; Mark Lemley; Rafael Baavour; Nathaniel Roth; Piotr J Slomka Journal: J Nucl Med Date: 2013-01-15 Impact factor: 10.057